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Background: Rotavirus diarrhea is one of the most important causes of death among under-five children. Anti-rotavirus vaccination of these children may have a reducing effect on the disease.
Objectives: this study is intended to contribute to health policy-makers of the country about the optimal decision and policy development in this area, by performing cost-effectiveness and cost-utility analysis on anti-rotavirus vaccination for under-5 children.
Patients and Methods: A cost-effectiveness analysis was performed using a decision tree model to analyze rotavirus vaccination, which was compared with no vaccination with Iran’s ministry of health perspective in a 5-year time horizon. Epidemiological data were collected from published and unpublished sources. Four different assumptions were considered to the extent of the disease episode. To analyze costs, the costs of implementing the vaccination program were calculated with 98% coverage and the cost of USD 7 per dose. Medical and social costs of the disease were evaluated by sampling patients with rotavirus diarrhea, and sensitivity analysis was also performed for different episode rates and vaccine price per dose.
Results: For the most optimistic assumption for the episode of illness (10.2 per year), the cost per DALY averted is 12,760 and 7,404 for RotaTeq and Rotarix vaccines, respectively, while assuming the episode of illness is 300%, they will be equal to 2,395 and 354, respectively, which will be highly cost-effective. Number of life-years gained is equal to 3,533 years.
Conclusions: Assuming that the illness episodes are 100% and 300% for Rotarix and 300% for Rota Teq, the ratio of cost per DALY averted is highly cost-effective, based on the threshold of the world health organization (< 1 GDP per capita = 4526 USD). The implementation of a national rotavirus vaccination program is suggested.
Keywords: Rotavirus; Acute Diarrhea; Cost-Effectiveness; Iran; Children
Copyright © 2015, Growth & Development Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. BackgroundAcute diarrhea is responsible for nearly 1.9 million deaths per year in under-5 children (1). Disease caused by the virus varies from very mild disease with watery diarrhea to se-vere diarrhea with the loss of body water and electrolytes along with shock and death. During the first 5 years of life, each person may be infected with the virus at least once, which would result in one out of every five cases of refer-ring to the clinic, one out of every 65 cases of hospitaliza-tion be responsible for approximately forty percent of all cases of severe diarrhea in infants (2-6). The virus causes 527,000 (475,000 -580,000) deaths per year in under-2 chil-dren, almost all of which occur in developing countries (3-7). The latest statistics of the virus in Iran indicates that rotavirus in diarrheal cases is positive in more than 59.1% of hospital visits (7). Global incidence of rotavirus infections showed that the provision of clean water and good sanita-tion are less able to be effective in reducing the virus trans-
mission, and vaccination is the only effective primary pre-vention. It is important to note that over 85% of deaths from the disease occur in developing countries in Africa and Asia (6-12). High vaccine prices, along with the lack of awareness of the burden of disease and the efficacy and safety of the vaccine, has resulted in less use of the vaccine in routine vaccination programs of the low- and medium-income countries (9, 13, 14). Developing and low-income countries are facing financial challenges in the areas of purchasing and keeping new vaccines (12, 13, 15-17). In Iran, many stud-ies have shown the relatively high incidence of the disease, especially in diarrhea hospitalizations, which causes a high burden of disease and the occupancy of hospital beds. In addition to above cases, the limited budgets of the minis-try of health also require the need for studies on the cost-effectiveness, in order to prioritize and strengthen policies for the implementation of prevention programs.
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2. ObjectivesTherefore, this study is intended to contribute to health policy-makers of the country about the optimal decision and policy development in this area, by performing cost-effectiveness and cost-utility analysis on anti-rotavirus vaccination for under-5 children.
3. Patients and Methods
3.1. Model StructureA decision tree model in Tree-Age pro version 9 was ap-plied to calculate total vaccination cost minus medical cost of diarrhea saved by such an immunization program. In addition we estimated three outcomes of outpatient care, inpatient care, and death. Finally we calculated cost per DALY averted in the 5-year time horizon. Two different vaccination scenarios were determined in the study for two RotaTeq and Rotarix vaccines, which were compared with a scenario without vaccination (Figure 1). For each scenario, four assumptions were considered on the basis of the disease incidence rates and different episodes, for which DALY was separately estimated. The model followed a 2010 Iranian birth cohort of 1,300,000 children.The treatment costs of rotavirus occurring over 5-year period were estimated. To analyze the costs, the total cost of the vaccination program was estimated in the interven-tion scenario in the 5-year time horizon. In addition, the direct costs of medical care and treatment as well as the indirect social costs of rotavirus occurring over 5-year pe-riod were estimated in non-vaccination scenario on the ba-sis of incidence estimates for each episode scenario, then the medical and treatment cost savings was calculated according to vaccine efficacy. Cost of vaccination program and treatment cost of rotavirus calculated in base year and then adjusted with annual discount rate of 3% and infla-tion factor. After all the epidemiological data and the data on cost and efficacy were entered into the model, the cost-effectiveness analysis was finally obtained by calculating the cost per DALY averted for every scenario.
All costs were expressed in US dollars. The monetary values in Iranian Rials were converted into United States dollars (USD) based on the average exchange rate in base year 2010 (1 USD = 20,000 Rials).3.2. Parameter Estimation
3.2.1. Epidemiological DataSince in general there was no comprehensive statistics on rotavirus diarrhea in Iran, a systematic review and me-ta-analysis was performed and then the pooled estimates were calculated for proportion of rotavirus gastroenteri-tis to obtain a relatively comprehensive epidemiological proportion of disease in the country. On the basis of the systematic review overall pooled estimate of infection with rotavirus among cases of gastroenteritis was 0.35 (95% CI, 0.28 - 0.41), pooled estimates for hospitalized chil-dren and outpatient visits were 0.39 (95% CI, 0.30 - 0.48) and 0.31 (95% CI, 0.23 - 0.38), respectively (18). Diarrhea epi-sodes in Iran were estimated based on four assumptions from the department of IMES database, expert panel and WHO-EMRO estimate. The total number of rotavirus di-arrhea cases was calculated by multiplying the diarrhea cases based on four assumptions for the incidence of diarrheal disease in Iran by the percentage of rotavirus infection of about 35% (Table 1). The software DISMOD was used to estimate other epidemiological parameters. The primary inputs to the software included the overall mortality rate of the country’s population on the basis of different age groups separately from the IRMIDHS data-base, the number of estimated populations in 2010 from population division of the ministry of health and other calculated disease parameters such as disease duration. The resulting outputs of the software were evaluated in terms of plausibility, and the burdens of disease from ro-tavirus diarrhea were determined for all the assumptions in WHO’s DALY computational sheet after modeling the epidemiologic data and fitting the data. Disability weight associated with the disease, time discount rate and differ-ent age values were used to calculate DALY (Table 2).
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Figure 1. Decision Tree Model Structure for Implementation Anti Rotavirus Vaccination for Under 5 Children in Iran
Shakerian S et al.
3Iran J Pediatr. 2015;25(4):e2766
3.3. Vaccines EfficacyThe pooled estimates of rotavirus vaccine efficacy in vaccine trials, which were derived during a systematic review, were used for the efficacy and safety of the vac-cines. On the basis of systematic review the pooled es-timate for vaccine efficacy for rotarix and RotaTeq was 80% (95% CI: 0.68 - 0.87) and 70% (95%CI: 0.65 - 0.85) re-spectively against Rotavirus infection. The results were described in detail in efficacy paper (19). Characteristics of studies used to derive the efficacy rate of the RotaTeq and Rotarix vaccines, along with different outcomes, are presented in Table 3.
3.4. Vaccines CostThe costs of providing RotaTeq and Rotarix vaccines were calculated according to the cohort number of live birth per year, the rate of vaccine coverage, the number of doses required for a fully immunized child, the wast-age rate, and the price per dose (Table 4). Rotavirus vac-cine coverage was predicted to be the same as of DPT 
coverage rates in Iran from CDC database and it was as-sumed that 98% of children would be fully immunized. The major costs associated with the implementation of the vaccination program (such as the costs of trans-portation, cold chain storage, training and stationery, surveillance and maintenance) have been estimated us-ing the models that were based on data from previous vaccinations and the clinical guidelines of the world health organization. Since oral vaccines have been used in the study, the costs of syringes and alcohol were not calculated, and personnel costs were also ignored be-cause of the simultaneous injection of other routine vaccines. We assumed 10 years as useful working life of vehicle and refrigerators along with discount rate to calculate annualized capital system cost. In addition all cost categories in base year were measured for the following 5 years on the basis of predicted value of vac-cine price and number of birth cohort and adjusted with inflation and discount factor in Model. Informa-tion about costs was obtained from the experts of the ministry of health.
Table 1. Summary of Model Epidemiologic Parameters
Parameter Value Source
Population of under five children in 2010 5948599 IHM
Diarrhea rate Iran 1th scenario 10.20% IHM
Diarrhea rate Iran 2th scenario 17.34% IHM
Diarrhea rate Iran 3th scenario 100% Expert panel
Diarrhea rate Iran 4th scenario 300% EMRO-WHO
Proportion of rotavirus infection in acute gastroenteritis 35% (28%-41%) Calculated -Meta analysis [30]
Number of under five mortality due to acute gastroenteritis 161 IRMIDHS
Number of under five mortality due to rotavirus infection diarrhea 58 Literature
Under five mortality rate due to rotavirus infection diarrhea per 100000 1 Calculated
Table 2. Burden of Disease Parameters
Index 1th Scenario 2th Scenario 3th Scenario 4th Scenario
Total diarrhea rate (episode) in Iran, % 10.20 17.34 100 300
Total diarrhea in Iran 606757 1031487 5948599 17845797
Total number of rotavirus infection diarrhea in Iran 218433 371335 2141496 6424487
DALY 21582 22494 31946 56614
Table 3. Summery of Vaccine Efficacies a
Vaccine Efficacy RotaTeq Rotarix
Severe and none severe 70 80
Hospitalization 90 94
Death 84 84a  Data are presented as %.
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Table 4. Vaccine Cost Parameters
Parameter RotaTeq Rotarix Source
Number of dose per vial 1 1 WHO
Coverage rate, % 98 98 IHM
Number of cohort in base year 2010 1,300,000 1,300,000 IHM
Wastage rate factor 1.05 1.05 WHO
Number of doses per fully immunized child 3 2 WHO
The total of number of dose supplied 4013100 2675400 Calculated a
Price per dose 7 7 IHM
Total vaccine supplies cost in base year 28091700 18727800 Calculated b
Vaccine delivery vehicles 65000 52000 IHM
Cold chain storage 71624 57299 IHM
Training material 81250 81250 IHM
Surveillance 31250 31250 IHM
Redesign of stationery 93750 93750 IHM
Transport maintenance 48000 48000 IHM
Cold chain maintenance 22997 22997 IHM
Total vaccine system cost in 5 Year 196283401 131856059 calculateda  The total of number of dose supplied = birth cohort * coverage rate * number of dose per fully immunized child * wastage rate.b  Total vaccine supplies cost = the total number of dose supplied * price per dose.
3.5. Health Service CostsDirect and indirect treatment costs were calculated for inpatient and outpatient cases in public and private hos-pitals.The rates of use of inpatient and outpatient servic-es in the public and private units were obtained from the statistics of the ministry of health, which were applied in the calculation. Utilization rates for outpatient services in private units were equal to 67.7%. The rate of use of in-patient units by people was higher in the public sector and was reported at 84%. Average cost of hospitalization has been calculated based on a sample of 50 patients who were hospitalized for viral diarrhea in Hazrat Rasoul Hospital in Tehran. The inpatient cost included daily room charge, diagnostic tests, medications, inpatient visits and outpatient con-sultation and out of pocket medical expenditure.In order to calculate the outpatient services costs we extracted pharmaceutical items, diagnostic tests, and outpatient visits after consultation with expert’s panel including health professionals, GPs, pediatric assistants and pediatricians in public and private sector.Different tariff rates in the public and private sectors have been used to calculate the cost per unit. In addition, the indirect costs of treatment, including the opportu-nity cost, were calculated using the human capital ap-proach on the basis of data on the duration of diarrheal illnesses as 5 day in hospital and 2 days at home and esti-mate of daily wages was based on basic wages (USD 5.5/day) in Iran. After calculation of average cost, total cost for under-5 children was calculated using the incidence 
rate resulting from modeling in the population of un-der-5 children. Given the rate of use of inpatient and out-patient units for different assumptions of incidence, the overall results of values are shown in Table 5.
3.6. Cost-Effectiveness AnalysisAnalysis of cost effectiveness for rotavirus vaccination was calculated in comparison with the case of no vacci-nation program with ministry of health prospective. To estimate the incremental cost-effectiveness, the differ-ence between the costs in both scenarios was divided by the difference between the amounts of DALY averted, ac-cording to the following formula. In addition, the WHO threshold rate was used to interpret the incremental cost-effectiveness.ICER = total vaccination cost-Cost saved/DALY without vaccine-DALY with vaccine
4. ResultsThe results of the evaluation of the efficacy of the Ro-taTeq and Rotarix vaccines, which were obtained from the previous studies, show that the efficacy of RotaTeq vaccine was 0.7, 0.9, and 0.84 for the outcomes of gen-eral cases of illness, cases of hospitalization and death cases, respectively, while these rates were obtained at 0.8, 0.94, and 0.84 for the Rotarix vaccine, respectively. The results of the vaccine efficacy are presented in Table 4. Also, results of the systematic review and meta-anal-
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ysis performed in the reference year for the proportion of rotavirus gastroenteritis show that, overall pooled estimate of proportion of rotavirus gastroenteritis in Iran was 0.35 (95 CI: 0.28 - 0.41). Pooled estimate for in-patient and outpatient cases was 0.39 (95 CI: 0.30- 0.48) and 0.31 (95 CI: 0.23 - 0.38.) respectively. The results of the proportion of rotavirus in Iran in detail are present-ed in another paper (18).The vaccine supplies cost of RotaTeq and Rotarix were estimated at USD 192,540,723 and USD 128,360,482 re-spectively (Table 5). In addition, the total cost of the vac-cination program was estimated at USD 196,283,401 and USD 131,856,059 including cold chain storage, transpor-tation, training material, redesign of stationery, sur-veillance, and maintenance for the RotaTeq and Rotarix vaccines, respectively (Table 4). The incremental system cost of the vaccination program is USD 0.31 for RotaTeq and USD 0.29 for Rotarix. Assuming the episode of dis-ease is 100%, the total number of the patients amounts to 2,141,496, while the total amount of DALY for the disease is equal to 31,964. In this case, the total direct and indirect medical costs are equal to USD 48,227,829 (Table 5). Health service cost per children was estimat-ed at USD 63 in general cases, USD 1163 for admissions, and USD 146 for homecare and outpatient treatments. Findings from the economic evaluation showed that as-suming the episode of disease is 100%, with a minimum efficacy of 70% for Rota Teq and 80% for Rotarix vaccines, can avert 1,499,047 and 1,742,188 cases of disease as well as 22,362 and 25,557 of DALY, respectively (Table 5). Con-
sidering the 58 cases of death from rotavirus diarrhea in under-5 children, life-years gained were calculated equal to 3,533 years for both RotaTeq and Rotarix vac-cines. For all the outcomes, the social, and medical cost saved have also been estimated at over 33 and 38 mil-lion dollars for RotaTeq and Rotarix in the population of under-5 children, respectively. For the amount of the episode above, the costs per DALY averted is equal to 7268 and 3650, respectively, which represents the highly cost-effectiveness of the vaccination program for Rotarix on the basis of GDP per capita for Iran in 2010 (less than 1 GDP = 4526 US $) and cost effective for RotaTeq (less than three times the GDP = 13578). Also, Ro-taTeq vaccine is highly cost effective assumed that the episode of disease is 300% (Table 6).4.1. Sensitivity AnalysisWe considered uncertainty related to burden of disease parameter (Table 2) and vaccine price per dose. Results of two way sensitivity analysis for cost-effectiveness, which was made for different amounts of vaccine price (USD 10 and USD 15), and the different episode of disease in the four scenarios showed that increasing the vaccine prices up to USD 10, rotavirus vaccination was not cost-effective in low episode of rotavirus (first scenario). When vaccine price rises up to USD 15 RotaTeq vaccine remains cost ef-fective in high episode of disease (100% and 300%). Re-garding Rotarix in scenario analysis, this vaccine was not cost effective with vaccine price up to USD 15 in lower epi-sode of disease (Table 7).
Table 5. Total Estimated Cost and Health Care Utilization Measures
Episode, % No Vaccine RotaTeq Rotarix
Total 
Cases
Total 
DALY
Social and 
Medical 
Cost
Total 
Cases 
Averted
Total 
DALY 
Averted
Social and 
Medical 
Cost Saved
Total 
Cases 
Averted
Total 
DALY 
Averted
Social and 
Medical 
Cost Saved
10.20 218433 21582 5033395 152903 15107 3523376 167419 17266 4026716
17.34 371335 22494 8476862 259935 15746 5933803 302096 17995 6781489
100 2141496 31946 48227830 1499047 22362 33759481 1742188 25557 38582264
300 6424487 56614 144797645 4497141 39630 101358352 5226567 45292 115838116
Table 6. Cost-Effectiveness Result
Episode, % Cost Per DALY Averted Cost Per Case Averted
RotaTeq Rotarix RotaTeq Rotarix
10.20 12760 7404 1261 764
17.34 12089 6951 732 414
100 7268 3650 108 54
300 2395 354 21 3
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Table 7. Two Way Sensitivity Analyses
Total Rotavirus Episode per 100,000 Vaccine Price in Base Year a ICER RotaTeq ICER Rotarix
3672 10 16186 9402
6243 10 15376 8868
36000 10 9582 5000
108000 10 3701 1115
3672 15 23380 13599
6243 15 22278 12895
36000 15U 14443 7835
108000 15 6444 2715a USD.
5. DiscussionThe results of the study showed that in the case of program implementation, the social costs of treatment are reduced by over 70% in RotaTeq and 80% in Rotarix. Assuming there are the lowest episode (10 out of every 100 children are affected by diarrhea episodes per year) to the highest number of attacks of diarrhea (three epi-sodes of diarrhea per child per year), the costs prevent-ed by the implementation of program vary from over 4 to 115 million dollars in Rotarix and from about 3 to 101 million dollars in RotaTeq, as district statistics suggest. The number of incidences to the prevented disease has ranged from 167,416 to over 5 million episodes of the ill-ness in Rotarix and 152903 to over 4 million episodes in RotaTeq. In the above rates, cost per DALY averted and cost per case averted (Table 6) represents the effective implementation of the program.The study’s results of the sensitivity analysis (Table 7), also, showed that the incremental cost-effectiveness ratio increases with the vaccine prices, but ultimately, the results still remain cost-effective in higher episode of disease. According to the review, cases of rotavirus gastroenteritis comprise over one third of all cases of acute gastroenteritis admitted to clinics and hospitals in the country. In addition, this level was found to reach approximately 50% in the hospital studies, which rep-resents high rates of hospitalization due to rotavirus diarrhea and would be an economic burden on the gov-ernment and the community. Many studies were con-ducted on economic evaluation of anti-rotavirus vac-cines in different parts of the world, most of which have been cost-effective. A sample of the studies conducted in developing countries showed that rotavirus vacci-nation can annually prevent 228,000 deaths, 13.7 mil-lion hospital visits and 8.7 million adjusted life years in terms of disability and can cause approximately USD 188 million savings in treatment costs and 243 mil-lion dollars in social costs (20). At the rate of USD 5 per 
dose, the cost per adjusted year is equal to USD 88, USD 291 and USD 329 in terms the prevented disability for low-income, below average, and above average income countries, respectively (21) with the price of USD 7 per dose of vaccine and the illness episode reported by the ministry of health with a probability of 70% confidence (the rate has ranged from 114 to 958 for both RotaTeq and Rotarix vaccines in our country). Treatment of ro-tavirus in Vietnam annually costs about USD 5.3 million for the community. With a cost of approximately USD 7.26 per dose, the vaccination of infants is considered a cost-effective intervention in public health for the health system (22). In the United States, the comprehen-sive rotavirus vaccination program prevents from 1.08 million cases of acute diarrhea, 34000 hospitalizations, 95,000 cases of emergency admission and 227,000 vis-its to the doctor in the first 5 years of life (21). In a study to evaluate the economic burden of rotavirus infection, which took into account the burden of disease in un-der-7 children in some countries such as Belgium, it was expected that rotavirus gastroenteritis annually results in 5,600 hospitalizations (679 out of about one hundred thousand children) and 26,800 outpatient vis-its to pediatricians and GPs. The virus also causes 44600 attacks, whose economic burden is estimated at 7.7 and 12 million USD in direct and indirect costs, respective-ly (23). In addition, assuming the vaccine price is USD 2 per dose, cost per DALY averted is equal to USD 22 in Uzbekistan, which reaches about USD 117 with the price of USD 10 for each vaccine dose. Given the USD 700 per capita in this country in 2004, it is considered a cost-effective intervention. Given the above prices, the cost for the prevention of death was 734 dollars and 3864 dollars respectively (24). In Iran, the two vaccines are considered as highly cost-effective with regard to the standard criterion of the world health organization for cost-effective interventions (cost per DALY averted is 
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less than the per capita income that is equal to 4,526 dollars). Due to the high rates of vaccine efficacy, espe-cially in cases of hospitalization and severe illness, the decision to implement the program is noteworthy be-cause most of the financial burden in above cases is im-posed with the occupancy of hospital beds to the com-munity and government.One limitation of this study is that many of costs (such as intangible costs and some direct non-medical costs) are not considered due to the problems of estimation in the country. On the other hand, some complications such as rates of emergency admission and nosocomial cases of the disease were not included in the study be-cause of unavailability of reliable epidemiological data in the country. Maybe the preserved costs resulting from the program implementation increase because of all the complications created. It is important to note that rota-virus vaccination is recommended to be applied concur-rent with other routine vaccines because, as the reports suggest, it will result in a 30% - 40% reduction in the costs of the program implementation (8, 16). In terms of the safety of the RotaTeq and Rotarix vaccines, no serious complications were observed, and the main side effects were fever and mild systemic symptoms that can also be seen in other vaccines. Given that in our country, other fever vaccines are commonly prescribed with some rou-tine recommendations at the health centers, the costs of vaccine complications were not calculated in this study with regard to its co-administration with other routine vaccines. As shown in the table, although Rotarix is more cost-effective than RotaTeq, due to the cost-effectiveness of both vaccines, they have different effects on different strains, which should be carefully considered in the de-cision to select vaccines, considering the strains preva-lent in the country. In studies conducted in different regions, it was shown that the RotaTeq vaccine can more affect the strains G1, G2, G3, G4, or P1A while Rotarix vac-cine has more impact on the strains G1P (8). According a review of the studies conducted in the country, G4P and G3 are the most commonly reported types of strain (7, 25). However, to determine the strains prevalent in the country, larger studies with greater precision are sug-gested in order to choose the effective vaccine type.According the evidences regarding vaccine efficacy and safety for some effect in reducing the risk of severe forms of the disease, rotavirus vaccination based on the thresh-old set by the world health organization is cost-effective due to the high economic burden of the disease, and, if added to the national vaccination program, will contrib-ute towards optimal allocation of resources.
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